Edition:
United States

Shire PLC (SHP.L)

SHP.L on London Stock Exchange

4,676.50GBp
24 Mar 2017
Change (% chg)

11.50 (+0.25%)
Prev Close
4,665.00
Open
4,651.00
Day's High
4,714.00
Day's Low
4,643.50
Volume
1,646,635
Avg. Vol
2,312,557
52-wk High
5,377.00
52-wk Low
3,760.00

SHP.L

Chart for SHP.L

About

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas... (more)

Overall

Beta: 1.49
Market Cap(Mil.): £42,502.95
Shares Outstanding(Mil.): 905.17
Dividend: 20.64
Yield (%): --

Financials

  SHP.L Industry Sector
P/E (TTM): 63.61 29.17 29.94
EPS (TTM): 0.74 -- --
ROI: 1.70 13.48 13.01
ROE: 3.11 14.39 14.16

BRIEF-FDA grants fast track designation for Shire's Recombinant ADAMTS13

* Shire receives FDA fast track designation for Recombinant ADAMTS13 (SHP655) for treatment of hereditary thrombotic thrombocytopenic purpura Source text for Eikon: Further company coverage:

Mar 22 2017

BRIEF-FDA grants fast track designation for Shire's Recombinant Adamts13

* Shire Plc - United States Food And Drug Administration (FDA) has granted fast track designation for Recombinant Adamts13

Mar 22 2017

BRIEF-Shire receives European approval for label extension of Cinryze

* Shire receives european approval for label extension of Cinryze(C1 inhibitor) to prevent and treat hereditary angioedema (HAE) attacks in paediatric patients with hae

Mar 16 2017

BRIEF-Neos Therapeutics enters into a license agreement with Shire

* On March 6, 2017, Neos Therapeutics entered into a license agreement with Shire - SEC filing

Mar 10 2017

BRIEF-Argenx announces extension of therapeutic antibody alliance with Shire

* Reg-Argenx announces extension of therapeutic antibody alliance with Shire plc to advance the discovery and development of novel human therapeutic antibodies for diverse rare and unmet diseases for a further year until May 30, 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Feb 27 2017

BRIEF-Shire reports positive results in phase 1b study of skin swelling drug Lanadelumab

* No serious adverse events or discontinuations due to adverse events were observed at all doses studied

Feb 23 2017

UPDATE 2-China updates key drug list in boost for Big Pharma

* GSK, AZ, Shire welcome update (Adds GSK statement, analyst comment, details)

Feb 23 2017

Pharma group Shire produces top-of-the-range earnings

LONDON Pharmaceuticals group Shire on Thursday said it was extremely optimistic about long-term growth after reporting a 12 percent rise in earnings for the past year in which it made its largest ever acquisition.

Feb 16 2017

UPDATE 1-Pharma group Shire produces top-of-the-range earnings

* Shares rise 6 pct (Adds CEO comments, analyst reaction, shares)

Feb 16 2017

Pharma group Shire posts earnings rise at top of guidance

LONDON, Feb 16 Pharmaceuticals group Shire reported a 12 percent rise in full-year earnings after what it said was a transformational year marked by its largest acquisition to date, adding that it is extremely optimistic on long-term growth prospects.

Feb 16 2017

More From Around the Web

Earnings vs. Estimates